Connection

SUSAN HILSENBECK to Female

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Female.
Connection Strength

0.948
  1. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8.
    View in: PubMed
    Score: 0.015
  2. To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.
    View in: PubMed
    Score: 0.015
  3. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54.
    View in: PubMed
    Score: 0.014
  4. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10.
    View in: PubMed
    Score: 0.012
  5. Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007 Oct; 5(4):308-15.
    View in: PubMed
    Score: 0.011
  6. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.010
  7. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
    View in: PubMed
    Score: 0.010
  8. A comprehensive atlas of AAV tropism in the mouse. Mol Ther. 2025 Mar 05; 33(3):1282-1299.
    View in: PubMed
    Score: 0.009
  9. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
    View in: PubMed
    Score: 0.009
  10. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.009
  11. Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study. JCO Precis Oncol. 2024 Sep; 8:e2400187.
    View in: PubMed
    Score: 0.009
  12. Gambian Mothers Lack Obstetric Danger Sign Knowledge, But Educational Intervention Shows Promise. Ann Glob Health. 2024; 90(1):31.
    View in: PubMed
    Score: 0.009
  13. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
    View in: PubMed
    Score: 0.009
  14. The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 02 05; 26(1):23.
    View in: PubMed
    Score: 0.009
  15. Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System. Am J Prev Med. 2024 03; 66(3):540-547.
    View in: PubMed
    Score: 0.009
  16. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
    View in: PubMed
    Score: 0.008
  17. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
    View in: PubMed
    Score: 0.008
  18. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147.
    View in: PubMed
    Score: 0.008
  19. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
    View in: PubMed
    Score: 0.008
  20. Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal. Gynecol Oncol. 2022 06; 165(3):642-649.
    View in: PubMed
    Score: 0.008
  21. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.
    View in: PubMed
    Score: 0.008
  22. Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10.
    View in: PubMed
    Score: 0.007
  23. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
    View in: PubMed
    Score: 0.007
  24. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
    View in: PubMed
    Score: 0.007
  25. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
    View in: PubMed
    Score: 0.007
  26. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.007
  27. Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. Trials. 2020 Oct 21; 21(1):872.
    View in: PubMed
    Score: 0.007
  28. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.
    View in: PubMed
    Score: 0.007
  29. Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
    View in: PubMed
    Score: 0.007
  30. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
    View in: PubMed
    Score: 0.007
  31. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
    View in: PubMed
    Score: 0.007
  32. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.007
  33. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
    View in: PubMed
    Score: 0.007
  34. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.
    View in: PubMed
    Score: 0.006
  35. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
    View in: PubMed
    Score: 0.006
  36. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.
    View in: PubMed
    Score: 0.006
  37. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
    View in: PubMed
    Score: 0.006
  38. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
    View in: PubMed
    Score: 0.006
  39. Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.
    View in: PubMed
    Score: 0.006
  40. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.
    View in: PubMed
    Score: 0.006
  41. Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res. 2019 01 01; 79(1):61-71.
    View in: PubMed
    Score: 0.006
  42. Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst. 1998 Sep 02; 90(17):1247-8.
    View in: PubMed
    Score: 0.006
  43. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
    View in: PubMed
    Score: 0.006
  44. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
    View in: PubMed
    Score: 0.006
  45. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.006
  46. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
    View in: PubMed
    Score: 0.006
  47. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87.
    View in: PubMed
    Score: 0.006
  48. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
    View in: PubMed
    Score: 0.006
  49. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773.
    View in: PubMed
    Score: 0.006
  50. NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813.
    View in: PubMed
    Score: 0.005
  51. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
    View in: PubMed
    Score: 0.005
  52. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
    View in: PubMed
    Score: 0.005
  53. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
    View in: PubMed
    Score: 0.005
  54. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
    View in: PubMed
    Score: 0.005
  55. CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.
    View in: PubMed
    Score: 0.005
  56. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
    View in: PubMed
    Score: 0.005
  57. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.005
  58. Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6.
    View in: PubMed
    Score: 0.005
  59. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21.
    View in: PubMed
    Score: 0.005
  60. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
    View in: PubMed
    Score: 0.005
  61. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
    View in: PubMed
    Score: 0.005
  62. HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
    View in: PubMed
    Score: 0.005
  63. Practical p-value adjustment for optimally selected cutpoints. Stat Med. 1996 Jan 15; 15(1):103-12.
    View in: PubMed
    Score: 0.005
  64. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. Breast Cancer Res. 2015 Nov 18; 17:141.
    View in: PubMed
    Score: 0.005
  65. An essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Sci Signal. 2015 Sep 15; 8(394):ra92.
    View in: PubMed
    Score: 0.005
  66. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.
    View in: PubMed
    Score: 0.005
  67. The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214.
    View in: PubMed
    Score: 0.005
  68. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.005
  69. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
    View in: PubMed
    Score: 0.005
  70. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
    View in: PubMed
    Score: 0.005
  71. Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2. PLoS One. 2015; 10(1):e0117239.
    View in: PubMed
    Score: 0.005
  72. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.005
  73. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13.
    View in: PubMed
    Score: 0.005
  74. The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
    View in: PubMed
    Score: 0.005
  75. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82.
    View in: PubMed
    Score: 0.005
  76. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.005
  77. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
    View in: PubMed
    Score: 0.005
  78. Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 01; 74(5):1601-6.
    View in: PubMed
    Score: 0.005
  79. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
    View in: PubMed
    Score: 0.005
  80. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
    View in: PubMed
    Score: 0.004
  81. Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7.
    View in: PubMed
    Score: 0.004
  82. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
    View in: PubMed
    Score: 0.004
  83. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
    View in: PubMed
    Score: 0.004
  84. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife. 2013 Dec 31; 2:e00996.
    View in: PubMed
    Score: 0.004
  85. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51.
    View in: PubMed
    Score: 0.004
  86. Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.
    View in: PubMed
    Score: 0.004
  87. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.
    View in: PubMed
    Score: 0.004
  88. Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? AJR Am J Roentgenol. 2013 Aug; 201(2):456-61.
    View in: PubMed
    Score: 0.004
  89. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
    View in: PubMed
    Score: 0.004
  90. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80.
    View in: PubMed
    Score: 0.004
  91. Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9.
    View in: PubMed
    Score: 0.004
  92. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.004
  93. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11.
    View in: PubMed
    Score: 0.004
  94. Fibroblast growth factor receptor signaling is essential for normal mammary gland development and stem cell function. Stem Cells. 2013 Jan; 31(1):178-89.
    View in: PubMed
    Score: 0.004
  95. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013; 15(5):R77.
    View in: PubMed
    Score: 0.004
  96. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.
    View in: PubMed
    Score: 0.004
  97. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65.
    View in: PubMed
    Score: 0.004
  98. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.004
  99. The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62.
    View in: PubMed
    Score: 0.004
  100. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43.
    View in: PubMed
    Score: 0.004
  101. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.
    View in: PubMed
    Score: 0.004
  102. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6.
    View in: PubMed
    Score: 0.004
  103. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992; 22(3):197-206.
    View in: PubMed
    Score: 0.004
  104. Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.
    View in: PubMed
    Score: 0.004
  105. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.004
  106. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.
    View in: PubMed
    Score: 0.004
  107. Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.
    View in: PubMed
    Score: 0.004
  108. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377.
    View in: PubMed
    Score: 0.004
  109. A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
    View in: PubMed
    Score: 0.004
  110. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.
    View in: PubMed
    Score: 0.004
  111. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
    View in: PubMed
    Score: 0.004
  112. Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
    View in: PubMed
    Score: 0.004
  113. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
    View in: PubMed
    Score: 0.004
  114. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
    View in: PubMed
    Score: 0.004
  115. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.004
  116. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
    View in: PubMed
    Score: 0.004
  117. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.004
  118. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93.
    View in: PubMed
    Score: 0.004
  119. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
    View in: PubMed
    Score: 0.004
  120. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79.
    View in: PubMed
    Score: 0.003
  121. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25.
    View in: PubMed
    Score: 0.003
  122. P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis. Breast Cancer Res. 2010; 12(5):R73.
    View in: PubMed
    Score: 0.003
  123. Drain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81.
    View in: PubMed
    Score: 0.003
  124. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26.
    View in: PubMed
    Score: 0.003
  125. Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug; 38(2):181-6.
    View in: PubMed
    Score: 0.003
  126. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.
    View in: PubMed
    Score: 0.003
  127. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.003
  128. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 05 15; 160(2):268-76.
    View in: PubMed
    Score: 0.003
  129. Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. Arch Surg. 1990 Mar; 125(3):364-9.
    View in: PubMed
    Score: 0.003
  130. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
    View in: PubMed
    Score: 0.003
  131. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.
    View in: PubMed
    Score: 0.003
  132. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.
    View in: PubMed
    Score: 0.003
  133. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.
    View in: PubMed
    Score: 0.003
  134. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. Breast Cancer Res. 2009; 11(4):R61.
    View in: PubMed
    Score: 0.003
  135. Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.
    View in: PubMed
    Score: 0.003
  136. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.003
  137. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009 Nov; 118(2):369-75.
    View in: PubMed
    Score: 0.003
  138. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
    View in: PubMed
    Score: 0.003
  139. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.
    View in: PubMed
    Score: 0.003
  140. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
    View in: PubMed
    Score: 0.003
  141. Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
    View in: PubMed
    Score: 0.003
  142. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008 Dec; 26(12):3205-9.
    View in: PubMed
    Score: 0.003
  143. Early termination of a phase II clinical trial. Control Clin Trials. 1988 Sep; 9(3):177-88.
    View in: PubMed
    Score: 0.003
  144. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.
    View in: PubMed
    Score: 0.003
  145. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res. 2008 Jun 15; 68(12):4674-82.
    View in: PubMed
    Score: 0.003
  146. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.
    View in: PubMed
    Score: 0.003
  147. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
    View in: PubMed
    Score: 0.003
  148. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.003
  149. Effect of BioGlue on the incidence of pancreatic fistula following pancreas resection. J Gastrointest Surg. 2008 May; 12(5):882-90.
    View in: PubMed
    Score: 0.003
  150. The role of single nucleotide polymorphisms in breast cancer metastasis. Breast Cancer Res. 2008; 10(1):301.
    View in: PubMed
    Score: 0.003
  151. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.
    View in: PubMed
    Score: 0.003
  152. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.
    View in: PubMed
    Score: 0.003
  153. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.
    View in: PubMed
    Score: 0.003
  154. Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.
    View in: PubMed
    Score: 0.003
  155. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.003
  156. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006 Sep 01; 12(17):5047-54.
    View in: PubMed
    Score: 0.003
  157. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704.
    View in: PubMed
    Score: 0.003
  158. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
    View in: PubMed
    Score: 0.003
  159. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
    View in: PubMed
    Score: 0.003
  160. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.003
  161. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
    View in: PubMed
    Score: 0.003
  162. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s.
    View in: PubMed
    Score: 0.003
  163. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res. 2006; 8(1):R6.
    View in: PubMed
    Score: 0.002
  164. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.002
  165. Transcriptional profiling of mammary gland side population cells. Stem Cells. 2006 Apr; 24(4):1065-74.
    View in: PubMed
    Score: 0.002
  166. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
    View in: PubMed
    Score: 0.002
  167. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology. 2005 Aug; 146(8):3490-505.
    View in: PubMed
    Score: 0.002
  168. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.002
  169. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9.
    View in: PubMed
    Score: 0.002
  170. The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4.
    View in: PubMed
    Score: 0.002
  171. Research with stored biological samples: what do research participants want? Arch Intern Med. 2005 Mar 28; 165(6):652-5.
    View in: PubMed
    Score: 0.002
  172. Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
    View in: PubMed
    Score: 0.002
  173. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
    View in: PubMed
    Score: 0.002
  174. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
    View in: PubMed
    Score: 0.002
  175. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3.
    View in: PubMed
    Score: 0.002
  176. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004 May 15; 64(10):3525-32.
    View in: PubMed
    Score: 0.002
  177. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.002
  178. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
    View in: PubMed
    Score: 0.002
  179. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.
    View in: PubMed
    Score: 0.002
  180. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
    View in: PubMed
    Score: 0.002
  181. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.002
  182. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80.
    View in: PubMed
    Score: 0.002
  183. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
    View in: PubMed
    Score: 0.002
  184. Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
    View in: PubMed
    Score: 0.002
  185. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
    View in: PubMed
    Score: 0.002
  186. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
    View in: PubMed
    Score: 0.002
  187. Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat. 2002 May; 73(1):75-83.
    View in: PubMed
    Score: 0.002
  188. Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.
    View in: PubMed
    Score: 0.002
  189. Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. J Endocrinol. 2001 Oct; 171(1):75-83.
    View in: PubMed
    Score: 0.002
  190. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42.
    View in: PubMed
    Score: 0.002
  191. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80.
    View in: PubMed
    Score: 0.002
  192. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
    View in: PubMed
    Score: 0.002
  193. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704.
    View in: PubMed
    Score: 0.002
  194. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000 Sep; 26(6):601-5.
    View in: PubMed
    Score: 0.002
  195. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.
    View in: PubMed
    Score: 0.002
  196. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.
    View in: PubMed
    Score: 0.002
  197. Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg. 2000 May; 62(5):656-61.
    View in: PubMed
    Score: 0.002
  198. Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27; 85(5):455-62.
    View in: PubMed
    Score: 0.002
  199. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
    View in: PubMed
    Score: 0.002
  200. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.002
  201. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
    View in: PubMed
    Score: 0.002
  202. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11.
    View in: PubMed
    Score: 0.001
  203. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.001
  204. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41.
    View in: PubMed
    Score: 0.001
  205. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.
    View in: PubMed
    Score: 0.001
  206. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol. 1997 Nov; 8(11):1063-74.
    View in: PubMed
    Score: 0.001
  207. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.
    View in: PubMed
    Score: 0.001
  208. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
    View in: PubMed
    Score: 0.001
  209. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr; 43(2):99-103.
    View in: PubMed
    Score: 0.001
  210. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol. 1997 Feb; 17(2):723-31.
    View in: PubMed
    Score: 0.001
  211. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
    View in: PubMed
    Score: 0.001
  212. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.
    View in: PubMed
    Score: 0.001
  213. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9.
    View in: PubMed
    Score: 0.001
  214. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.001
  215. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6.
    View in: PubMed
    Score: 0.001
  216. Signs of temporomandibular disorders in patients with horizontal mandibular deficiency. J Orofac Pain. 1996; 10(1):21-7.
    View in: PubMed
    Score: 0.001
  217. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86.
    View in: PubMed
    Score: 0.001
  218. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
    View in: PubMed
    Score: 0.001
  219. p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct; 1(10):1203-8.
    View in: PubMed
    Score: 0.001
  220. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
    View in: PubMed
    Score: 0.001
  221. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
    View in: PubMed
    Score: 0.001
  222. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
    View in: PubMed
    Score: 0.001
  223. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28; 77(1):25-32.
    View in: PubMed
    Score: 0.001
  224. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch. 1994; 424(2):187-93.
    View in: PubMed
    Score: 0.001
  225. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95.
    View in: PubMed
    Score: 0.001
  226. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.
    View in: PubMed
    Score: 0.001
  227. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
    View in: PubMed
    Score: 0.001
  228. Microinvasive carcinoma of the cervix. Cancer. 1992 Oct 15; 70(8):2121-8.
    View in: PubMed
    Score: 0.001
  229. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 07; 84(19):1486-91.
    View in: PubMed
    Score: 0.001
  230. Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992 Jul 01; 70(1):129-35.
    View in: PubMed
    Score: 0.001
  231. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992 Apr; 3(2):121-4.
    View in: PubMed
    Score: 0.001
  232. Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
    View in: PubMed
    Score: 0.001
  233. Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat. 1992; 22(3):251-62.
    View in: PubMed
    Score: 0.001
  234. Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9.
    View in: PubMed
    Score: 0.001
  235. Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.
    View in: PubMed
    Score: 0.001
  236. Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991 May; 77(5):729-34.
    View in: PubMed
    Score: 0.001
  237. Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol. 1990 Sep; 38(3):315-22.
    View in: PubMed
    Score: 0.001
  238. Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. J Surg Res. 1988 Dec; 45(6):523-30.
    View in: PubMed
    Score: 0.001
  239. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988 Jun; 19(6):705-12.
    View in: PubMed
    Score: 0.001
  240. Toxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506.
    View in: PubMed
    Score: 0.001
  241. Cancer among Haitians in Florida. Cancer. 1987 Jan 01; 59(1):184-8.
    View in: PubMed
    Score: 0.001
  242. Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.